The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
Site Search
Showing 71 - 80 of 259 results
News
|
|
2 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
3 min read
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
News
|
|
3 min read
News
|
|
2 min read
News
|
|
2 min read
Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.
News
|
|
4 min read
The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.
News
|
|
5 min read